Skip to main content

Table 2 NSAID use and risk of breast cancer overall and by subtype, California Teachers Study, 2005–2012

From: Regular and low-dose aspirin, other non-steroidal anti-inflammatory medications and prospective risk of HER2-defined breast cancer: the California Teachers Study

  

Breast cancera

HR+/HER2–a

HR+/HER2+b

HR–/HER2−c

HR–/HER2+d

Any NSAIDe

 No NSAID past 3 years

Cases, n

514

349

35

55

17

HRR

1.0

1.0

1.0

1.0

1.0

 Former/irregular

Cases, n

154

105

11

12

5

HRR

1.04

1.04

1.11

0.79

1.03

95% CI

0.86–1.24

0.83–1.29

0.56–2.20

0.42–1.48

0.38–2.81

 Current, 3+ tablets/week

Cases, n

692

481

65

58

18

HRR

0.90

0.91

1.30

0.77

0.74

95% CI

0.80–1.01

0.79–1.05

0.86–1.98

0.53–1.12

0.38–1.45

 Unknown

Cases, n

97

63

9

13

4

HRR

1.16

1.09

1.73

1.58

1.45

95% CI

0.93–1.44

0.83–1.43

0.83–3.61

0.86–2.90

0.48–4.37

Low-dose aspirin

 No NSAID past 3 yearse

Cases, n

514

349

35

55

17

HRR

1.0

1.0

1.0

1.0

1.0

 No low-dose aspirin use but use of 1+ type(s)

Cases, n

400

281

34

33

10

HRR

0.99

0.93

1.21

1.19

2.59

95% CI

0.82–1.19

0.75–1.17

0.64–2.29

0.63–2.25

0.75–8.94

 Former/irregular

Cases, n

104

71

7

6

4

HRR

0.95

0.88

1.06

0.70

1.55

95% CI

0.75–1.19

0.67–1.16

0.45–2.50

0.29–1.67

0.48–4.99

 Current, 3+ tablets/week

Cases, n

338

230

33

31

10

HRR

0.84

0.80

1.37

0.96

1.06

95% CI

0.72–0.98

0.66–0.96

0.81–2.32

0.59–1.55

0.46–2.45

 Unknown

Cases, n

101

67

11

13

3

HRR

0.84

0.73

2.12

1.61

0.93

95% CI

0.62–1.14

0.50–1.07

0.84–5.34

0.68–3.79

0.19–4.68

Regular-dose aspirin

 No NSAID past 3 yearse

Cases, n

514

349

35

55

17

HRR

1.0

1.0

1.0

1.0

1.0

 No regular-dose aspirin use but use of 1+ type(s)

Cases, n

587

395

53

51

19

HRR

0.96

0.90

1.35

1.19

2.10

95% CI

0.80–1.16

0.72–1.12

0.72–2.51

0.64–2.22

0.65–6.82

 Former/irregular

Cases, n

73

59

4

4

1

HRR

1.12

1.27

1.03

1.03

0.96

95% CI

0.84–1.50

0.91–1.77

0.32–3.31

0.34–3.13

0.11–8.30

 Current, 3+ tablets/week

Cases, n

170

119

18

14

3

HRR

0.97

0.95

1.68

1.02

0.84

95% CI

0.80–1.18

0.75–1.20

0.90–3.17

0.54–1.93

0.24–3.03

 Unknown

Cases, n

113

76

10

14

4

HRR

1.13

1.04

1.70

2.21

2.35

95% CI

0.83–1.54

0.72–1.52

0.60–4.81

0.91–5.37

0.29–18.94

Ibuprofen

 No NSAID past 3 yearse

Cases, n

514

349

35

55

17

HRR

1.0

1.0

1.0

1.0

1.0

 No ibuprofen use but use of 1+ type(s)

Cases, n

472

317

43

44

19

HRR

0.96

0.92

1.14

1.19

2.22

95% CI

0.80–1.15

0.74–1.15

0.61–2.14

0.64–2.23

0.69–7.16

 Former/irregular

Cases, n

93

68

9

5

0

HRR

0.95

1.00

1.29

0.65

 

95% CI

0.74–1.23

0.74–1.35

0.56–2.97

0.24–1.76

 

 Current, 3+ tablets/week

Cases, n

263

190

20

20

4

HRR

1.04

1.09

1.00

0.90

0.66

95% CI

0.88–1.23

0.90–1.34

0.54–1.84

0.51–1.58

0.21–2.10

 Unknown

Cases, n

115

74

13

14

4

HRR

1.30

1.12

2.59

1.97

1.18

95% CI

0.99–1.70

0.79–1.56

1.16–5.79

0.90–4.31

0.19–7.46

Other non-steroidal

 No NSAID past 3 yearse

Cases, n

514

349

35

55

17

HRR

1.0

1.0

1.0

1.0

1.0

 No other non-steroidal use but use of 1+ type(s)

Cases, n

662

456

57

59

20

HRR

0.96

0.91

1.21

1.21

2.05

95% CI

0.80–1.15

0.73–1.13

0.65–2.25

0.65–2.26

0.63–6.63

 Former/irregular

Cases, n

64

38

7

6

3

HRR

0.98

0.77

1.62

1.41

3.14

95% CI

0.72–1.33

0.52–1.13

0.62–4.20

0.54–3.64

0.78–12.72

 Current, 3+ tablets/week

Cases, n

96

75

8

4

0

HRR

0.79

0.85

0.97

0.43

 

95% CI

0.62–1.00

0.64–1.13

0.41–2.25

0.15–1.26

 

 Unknown

Cases, n

121

80

13

14

4

HRR

1.17

1.00

2.74

1.91

1.94

95% CI

0.86–1.58

0.69–1.45

1.09–6.87

0.79–4.62

0.38–9.87

Cox-2 inhibitor

 No NSAID past 3 yearse

Cases, n

514

349

35

55

17

HRR

1.0

1.0

1.0

1.0

1.0

 No Cox-2 inhibitor use, but use of 1+ type(s)

Cases, n

706

492

59

59

19

HRR

0.96

0.90

1.22

1.22

2.68

95% CI

0.80–1.15

0.72–1.12

0.66–2.27

0.66–2.28

0.78–9.17

 Former/irregular

Cases, n

82

57

8

6

4

HRR

1.02

0.97

1.64

1.16

3.81

95% CI

0.78–1.34

0.70–1.34

0.68–3.97

0.46–2.96

1.07–13.57

 Current, 3+ tablets/week

Cases, n

30

15

5

4

1

HRR

0.92

0.63

2.60

1.74

1.74

95% CI

0.63–1.34

0.37–1.07

0.97–7.00

0.61–4.99

0.22–13.66

 Unknown

Cases, n

125

85

13

14

3

HRR

1.19

1.09

3.08

1.94

0.88

95% CI

0.88–1.61

0.75–1.58

1.21–7.88

0.79–4.75

0.15–5.22

  1. aCox regression models used age as the time metric, were stratified by age at the follow-up questionnaire, and were adjusted for age at menarche, parity and age at first full-term pregnancy, total months breastfeeding their offspring, history of a benign breast biopsy, family history of breast cancer (mother or sister), strenuous plus moderate physical activity, alcohol consumption, body mass index, menopausal status and hormone therapy use, and (except for “Any NSAID”) all of the other NSAIDS in the table (for each type: never past 3 years, former/irregular, current 3+ tablets/week, unknown). bCox regression models used age as the time metric, were stratified by age at the follow-up questionnaire, and were adjusted for parity and age at first full-term pregnancy, body mass index, and (except for “Any NSAID”) all of the other NSAIDS in the table. cCox regression models used age as the time metric, were stratified by age at the follow-up questionnaire, and were adjusted for race, alcohol consumption and its interaction with time-dependent age, and (except for “Any NSAID”) all of the other NSAIDS in the table. dCox regression models used age as the time metric, were stratified by age at the follow-up questionnaire, and were adjusted for total months breastfeeding their offspring, history of a benign breast biopsy, and (except for “Any NSAID”) all of the other NSAIDS in the table. eIncluded aspirin, low-dose aspirin, ibuprofen, Cox-2 inhibitor, and other NSAIDs currently used regularly (at least once a week) reported on the 10-year follow-up questionnaire. NSAID non-steroidal anti-inflammatory drug, HRR hazard rate ratio, CI confidence interval
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us